利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.073 秒)

    Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
    2.
    发明授权
    Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders 有权
    用于治疗ORL-1受体介导的疾病的羟基烷基取代的1,3,8-三氮杂螺[4.5]癸-4-酮衍生物

    公开(公告)号：US07582649B2

    公开(公告)日：2009-09-01

    申请号：US11242654

    申请日：2005-10-04

    申请人： Kathleen Battista ,  Gilles Bignan ,  Peter J. Connolly ,  Allen B. Reitz ,  Tina Morgan Ross ,  Malcolm Scott ,  Steven A. Middleton ,  Michael Orsini

    发明人： Kathleen Battista ,  Gilles Bignan ,  Peter J. Connolly ,  Allen B. Reitz ,  Tina Morgan Ross ,  Malcolm Scott ,  Steven A. Middleton ,  Michael Orsini

    IPC分类号： A61K31/438 ,  C07D471/10

    CPC分类号： C07D471/10

    摘要： The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse, neuropathic pain, acute pain, chronic pain, migraine, asthma, cough, psychosis, schizophrenia, epilepsy, hypertension, obesity, eating disorders, cravings, diabetes, cardiac arrhythmia, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, for improved cognition or memory and for mood stabilization.

    摘要翻译： 本发明涉及新的羟基烷基取代的1,3,8-三氮杂螺[4.5]癸-4-酮衍生物，其中所有变量如本文所定义，可用于治疗由ORL介导的病症和病症 -1 G蛋白偶联受体。 更具体地，本发明的化合物可用于治疗诸如焦虑，抑郁，恐慌，痴呆，躁狂症，双相情感障碍，物质滥用，神经性疼痛，急性疼痛，慢性疼痛，偏头痛，哮喘，咳嗽等疾病和病症 ，精神病，精神分裂症，癫痫，高血压，肥胖，进食障碍，渴望，糖尿病，心律失常，肠易激综合征，克罗恩病，尿失禁，肾上腺疾病，注意力缺陷障碍（ADD），注意缺陷多动障碍（ADHD） 疾病，用于改善认知或记忆和情绪稳定。

    Hydroxy alkyl substituted 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders
    3.
    发明授权
    Hydroxy alkyl substituted 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders 有权
    用于治疗orl-1受体介导的疾病的羟基烷基取代的1,3,8-三氮杂螺[4.5]癸-4-酮衍生物

    公开(公告)号：US07081463B2

    公开(公告)日：2006-07-25

    申请号：US10656934

    申请日：2003-09-05

    申请人： Kathleen Battista ,  Gilles Bignan ,  Peter J. Connolly ,  Allen B. Reitz ,  Tina Morgan Ross ,  Malcolm Scott ,  Steven A. Middleton ,  Michael Orsini

    发明人： Kathleen Battista ,  Gilles Bignan ,  Peter J. Connolly ,  Allen B. Reitz ,  Tina Morgan Ross ,  Malcolm Scott ,  Steven A. Middleton ,  Michael Orsini

    IPC分类号： H61K31/438 ,  C07D401/04

    CPC分类号： C07D471/10

    摘要： The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse, neuropathic pain, acute pain, chronic pain, migraine, asthma, cough, psychosis, schizophrenia, epilepsy, hypertension, obesity, eating disorders, cravings, diabetes, cardiac arrhythmia, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, for improved cognition or memory and for mood stabilization.

    摘要翻译： 本发明涉及新的羟基烷基取代的1,3,8-三氮杂螺[4.5]癸-4-酮衍生物，其中所有变量如本文所定义，可用于治疗由ORL介导的病症和病症 -1 G蛋白偶联受体。 更具体地，本发明的化合物可用于治疗诸如焦虑，抑郁，恐慌，痴呆，躁狂症，双相情感障碍，物质滥用，神经性疼痛，急性疼痛，慢性疼痛，偏头痛，哮喘，咳嗽等疾病和病症 ，精神病，精神分裂症，癫痫，高血压，肥胖，进食障碍，渴望，糖尿病，心律失常，肠易激综合征，克罗恩病，尿失禁，肾上腺疾病，注意力缺陷障碍（ADD），注意缺陷多动障碍（ADHD） 疾病，用于改善认知或记忆和情绪稳定。

    Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
    4.
    发明授权
    Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders 有权
    用于治疗ORL-1受体介导的疾病的羟基烷基取代的1,3,8-三氮杂螺[4.5]癸-4-酮衍生物

    公开(公告)号：US08778956B2

    公开(公告)日：2014-07-15

    申请号：US12327437

    申请日：2008-12-03

    申请人： Kathleen Battista ,  Gilles Bignan ,  Peter J. Connolly ,  Allen B. Reitz ,  Tina Morgan Ross ,  Malcolm Scott ,  Steven A. Middleton ,  Michael Orsini

    发明人： Kathleen Battista ,  Gilles Bignan ,  Peter J. Connolly ,  Allen B. Reitz ,  Tina Morgan Ross ,  Malcolm Scott ,  Steven A. Middleton ,  Michael Orsini

    IPC分类号： A61K31/438 ,  A61K31/5377

    CPC分类号： C07D471/10

    摘要： The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse, neuropathic pain, acute pain, chronic pain, migraine, asthma, cough, psychosis, schizophrenia, epilepsy, hypertension, obesity, eating disorders, cravings, diabetes, cardiac arrhythmia, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, for improved cognition or memory and for mood stabilization.

    摘要翻译： 本发明涉及新的羟基烷基取代的1,3,8-三氮杂螺[4.5]癸-4-酮衍生物，其中所有变量如本文所定义，可用于治疗由ORL介导的病症和病症 -1 G蛋白偶联受体。 更具体地，本发明的化合物可用于治疗诸如焦虑，抑郁，恐慌，痴呆，躁狂症，双相情感障碍，物质滥用，神经性疼痛，急性疼痛，慢性疼痛，偏头痛，哮喘，咳嗽等疾病和病症 ，精神病，精神分裂症，癫痫，高血压，肥胖，进食障碍，渴望，糖尿病，心律失常，肠易激综合征，克罗恩病，尿失禁，肾上腺疾病，注意力缺陷障碍（ADD），注意缺陷多动障碍（ADHD） 疾病，用于改善认知或记忆和情绪稳定。

    Aminothiazolones as estrogen related receptor-alpha modulators
    6.
    发明授权
    Aminothiazolones as estrogen related receptor-alpha modulators 有权

    公开(公告)号：US08445690B2

    公开(公告)日：2013-05-21

    申请号：US13028284

    申请日：2011-02-16

    申请人： Gilles Bignan ,  Micheal Gaul ,  Guozhang Xu ,  Bao-Ping Zhao

    发明人： Gilles Bignan ,  Micheal Gaul ,  Guozhang Xu ,  Bao-Ping Zhao

    IPC分类号： C07D417/14 ,  C07D211/32 ,  C07D415/00 ,  C07D419/00 ,  A61K31/4439 ,  A61K31/427 ,  A61K31/495 ,  A61K31/44 ,  A61K31/535 ,  A61K31/501 ,  A61K31/445 ,  A61K31/00

    CPC分类号： C07D417/06 ,  C07D417/14

    摘要： The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.